Interim data analysis of the ADAPT trial using the modified intent to treat (mITT) population re-evaluates Rocapuldencel-T for clinical benefit over standard of care.

Robert A. Figlin,Christopher G. Wood,Alicia H. Gamble,Ana Plachco,Marcus Norris,Joe M. Horvatinovich,Irina Tcherepanova,Charles Nicolette,Mark A. DeBenedette

Interim data analysis of the ADAPT trial using the modified intent to treat (mITT) population re-evaluates Rocapuldencel-T for clinical benefit over standard of care.

2018

Robert A. Figlin
Christopher G. Wood
Alicia H. Gamble
Ana Plachco
Marcus Norris
Joe M. Horvatinovich
Irina Tcherepanova
Charles Nicolette
Mark A. DeBenedette

4557Background: The Phase 3 ADAPT trial evaluates overall survival (OS) of Rocapuldencel-T (Roca) in combination (combo) with standard-of-care (SoC) for the treatment of newly diagnosed mRCC compar...

Keywords:

Interim
Population
Intensive care medicine
Intention-to-treat analysis
Physical therapy
Medicine
standard of care
newly diagnosed
overall survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations